After clearance based on clinical data, Truist Securities anticipates strong commercial adoption, probable adoption in NCCN guidelines, over 90% prescriber crossover between GEA and biliary tract ...
4d
Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors
TheFly reported on January 26 that Oppenheimer upgraded RLAY from Perform to Outperform and set a $14 price target.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results